Avoro Capital Advisors’s Immunomedics Inc IMMU Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-26,250,000
| Closed | -$2.23B | – | 52 |
|
|
2020
Q3 | $2.23B | Hold |
26,250,000
| – | – | 31.71% | 1 |
|
|
2020
Q2 | $930M | Buy |
26,250,000
+1,750,000
| +7% | +$51.2M | 18.39% | 1 |
|
|
2020
Q1 | $330M | Hold |
24,500,000
| – | – | 11.15% | 1 |
|
|
2019
Q4 | $518M | Buy |
24,500,000
+3,500,000
| +17% | +$61.7M | 15.22% | 1 |
|
|
2019
Q3 | $278M | Hold |
21,000,000
| – | – | 11.62% | 2 |
|
|
2019
Q2 | $291M | Buy |
21,000,000
+3,285,539
| +19% | +$49.4M | 10.07% | 2 |
|
|
2019
Q1 | $340M | Hold |
17,714,461
| – | – | 14.71% | 1 |
|
|
2018
Q4 | $253M | Hold |
17,714,461
| – | – | 15.11% | 1 |
|
|
2018
Q3 | $369M | Hold |
17,714,461
| – | – | 16.94% | 1 |
|
|
2018
Q2 | $419M | Buy |
17,714,461
+775,000
| +5% | +$15.6M | 16.14% | 1 |
|
|
2018
Q1 | $247M | Buy |
16,939,461
+875,000
| +5% | +$14.3M | 11.82% | 1 |
|
|
2017
Q4 | $260M | Buy |
16,064,461
+1,325,000
| +9% | +$15.6M | 16.83% | 1 |
|
|
2017
Q3 | $206M | Buy |
14,739,461
+4,251,385
| +41% | +$42.4M | 15.98% | 1 |
|
|
2017
Q2 | $92.6M | Hold |
10,488,076
| – | – | 11.69% | 1 |
|
|
2017
Q1 | $67.9M | Buy |
10,488,076
+1,224,736
| +13% | +$6.2M | 8.67% | 1 |
|
|
2016
Q4 | $34M | Buy |
9,263,340
+1,919,163
| +26% | +$5.68M | 6.87% | 2 |
|
|
2016
Q3 | $23.9M | Sell |
7,344,177
-1,212,780
| -14% | -$3.39M | 4.19% | 10 |
|
|
2016
Q2 | $19.9M | Buy |
8,556,957
+7,506,500
| +715% | +$25.1M | 4.41% | 10 |
|
|
2016
Q1 | $2.63M | Buy |
+1,050,457
| New | +$2.36M | 0.92% | 25 |
|
Avoro Capital Advisors's IMMU Position: Q4 2020 in Review
Avoro Capital Advisors sold out of Immunomedics Inc (IMMU) in Q4 2020, closing a stake of 26,250,000 shares — an estimated $2.23B sold.
Avoro Capital Advisors first reported a position in IMMU in Q1 2016 and held it in 19 quarters. The position peaked at $2.23B in Q3 2020. 0 funds tracked by Wall St. Rank hold IMMU as of Q4 2020.
- Avoro Capital Advisors reported no remaining Immunomedics Inc position as of Q4 2020 after selling out during the quarter.
- Avoro Capital Advisors sold 26,250,000 Immunomedics Inc shares in Q4 2020, an estimated $2.23B.
- Avoro Capital Advisors first reported a position in Immunomedics Inc in Q1 2016 and held it in 19 quarters.
- Avoro Capital Advisors's Immunomedics Inc position peaked at $2.23B in Q3 2020.
- 0 funds tracked by Wall St. Rank held Immunomedics Inc as of Q4 2020.
Based on Avoro Capital Advisors's 13F filing for Q4 2020, filed 16 Feb 2021.